SK Bioscience and Vaxxas partner to develop needle-free typhoid vaccine patch
24 Aug 2023
VaccineDrug Approval
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Preview
Source: Pharmaceutical Technology
The research collaboration has also received A$5.4m ($3.67m) in funding from Wellcome, a UK-based global charity. Image Credit: Andrey_Popov / Shutterstock.
South Korean biotech company SK Bioscience and Vaxxas have partnered to develop a typhoid conjugate vaccine that can be delivered by a needle-free patch.
The companies plan to reformulate SK’s SKYTyphoid vaccine for subcutaneous delivery using Vaxxas’s HD-MAP patch technology.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ribociclib Succinate in Non-Small Cell Lung Cancer GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Docetaxel in Non-Small Cell Lung Cancer GlobalData
View allCompanies IntelligenceSK IncSK Bioscience LtdInternational Vaccine InstituteWellcome Company LimitedSKS IncView all
In the press release, SK’s CEO Jaeyong Ahn said: “[The] utilisation of typhoid vaccines has been limited due to the requirement for vaccines that remain stable under varying temperatures and those that can be administered without medical supervision. This collaboration with Vaxxas provides an opportunity to overcome those challenges.”
The research collaboration has also received A$5.4m ($3.67m) in funding from Wellcome, a UK-based global charity. The agreement is contingent on providing vaccine access to low and middle-income countries.
Additionally, Wellcome, also known as the Wellcome Trust, is also entitled to a share of the revenue from the vaccine sales.
Typhoid fever is an infectious disease caused by Salmonella Typhi bacteria, commonly spread by drinking contaminated water. As per the World Health Organisation (WHO), approximately nine million people contract typhoid fever each year, mostly in developing countries in Africa, the Middle East, and South-East Asia.
SKYTyphoid is a polysaccharide-protein conjugate vaccine that targets diphtheria toxin protein and induces an immune response. The vaccine was developed in partnership with United Nations non-profit International Vaccine Institute (IVI) and was first approved in South Korea in May 2022.
The initial funding for SKYTyphoid was provided by the Bill & Melinda Gates Foundation. SK has applied for WHO Prequalification for the vaccine, which should be granted by the end of the year.
SK had a previous partnership with Wellcome and IVI to develop an infectious disease vaccine for diarrhoeal disease caused by nontyphoidal Salmonella infection.
The company recently signed a memorandum of understanding (MoU) with Thailand to transfer the company’s influenza vaccine (both trivalent and quadrivalent inactivated influenza vaccines) manufacturing process to the Government Pharmaceutical Organisation (GPO) to bolster Thailand’s vaccine infrastructure.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.